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ABSTRACT
Background: The long- term consequences of chemotherapy and radiotherapy result 
in a high prevalence and early onset of age- related chronic diseases in survivors. We 
aimed to examine whether childhood and adolescent cancer survivors (CS) demon-
strate biomarkers of accelerated aging.
Methods: We evaluated 50 young adult CS at 11 [8– 15] years after cancer diagnosis, 
and 30 healthy, age and sex- matched controls, who were unexposed to cancer ther-
apy. Using a machine- learning approach, we assessed factors discriminating CS from 
controls and compared selected biomarkers and lymphocyte subpopulations with data 
from the Framingham Heart Study (FHS) cohort and the Genotype Tissue Expression 
(GTEx) project.
Results: Survivors compared with controls had higher levels of C- reactive protein 
and fibrinogen. The surface expression of CD38 on T cells was increased, and there 
was an increase in the percentage of memory T cells in survivors, compared with the 
unexposed group. The relationships between above cell subpopulations and age were 
consistent in CS, FHS, and GTEx cohorts, but not in controls.
Conclusions: Young pediatric cancer survivors differ from age- related controls in 
terms of activation of the adaptive immune system and chronic, low- grade inflam-
mation. These changes resemble aging phenotype observed in older population. 
Further research in biomarkers of aging in young, adult childhood cancer survivors 
is warranted, as it may facilitate screening and prevention of comorbidities in this 
population.
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1 |  INTRODUCTION
Pediatric cancer survivors develop chronic conditions pre-
maturely and face a more significant disease burden than 
age- matched individuals never diagnosed with cancer. The 
prevalence of chronic diseases among childhood cancer sur-
vivors in their 20 s is similar to that of siblings in their 50 s.1 
Both cancer itself and treatment- related long- term conse-
quences contribute to accelerated aging,2 leading to prema-
ture aging phenotype in young cancer survivors.3– 5 Aging 
is associated with a chronic low- grade inflammation and an 
accumulation of senescent cells with a pro- inflammatory 
senescence- associated secretory phenotype.6 Age- related 
changes in the immune system, the reduction in the fre-
quency of naive T cells, increasing prevalence of activated, 
terminally differentiated, effector memory lymphocytes, and 
antigen- experienced memory B cells may contribute to the 
accumulation of senescent cells.7,8 The particular cluster of 
differentiation (CD) markers of the immune cells partici-
pates in the regulation of the immune response. During the 
activation process, the earliest activation markers are CD69 
and CD25.9 Expression of CD38 and HLA- DR is associated 
with late activation of mature T cells and production of pro- 
inflammatory cytokines.10
Rate of aging in the general population is controlled 
by genetic and biochemical processes. The potential hall-
marks of aging include genomic instability, telomere attri-
tion, epigenetic alterations, and cellular senescence among 
the others.11 In cancer survivors, exposure to chemotherapy 
and radiotherapy in childhood and adolescence during the 
development period may also accelerate aging by affect-
ing one or more of these processes and increase the risk 
of frailty. St. Jude Lifetime Cohort Study reports frailty in 
about 8% of survivors at a median age of 33 years,12 similar 
to rate described in adults from the general population aged 
over 65.13
Thus, while the risks of early onset of chronic, age- 
related conditions and frailty are increased in childhood 
cancer survivors, the mechanisms of this relationship re-
main elusive. Chronic, dysregulated inflammation may 
represent an essential mechanism of frailty and acceler-
ated aging.14 The effect of chronic inflammation on frailty 
development may surpass the effect of age.15 Persistent 
low- grade inflammation characterized by an increase in 
the production of pro- inflammatory cytokines and inflam-
matory markers may contribute to the early onset of age- 
related diseases.16 Cancer chemotherapy may well result in 
long- term immune alterations due to epigenetic remodel-
ing of immune cells providing the mechanism of increased 
development of inflammatory and age- related diseases in 
childhood and adolescent cancer survivors. It has been 
previously shown that pro- inflammatory cytokines can af-
fect DNA methylation. The initial inflammatory response 
to genotoxic agents as radiation and alkylating agents may 
contribute to epigenetic alterations of immune cells and 
lead to aberrant methylation, which accelerates the process 
of premature biological aging in young cancer survivors.17
The Framingham Heart Study (FHS), since the beginning 
in 1948, has been dedicated to the recognition of the common 
factors that contribute to cardiovascular diseases in three gen-
erations of participants.18 The Genotype- Tissue Expression 
(GTEx) project on the other hand is a database and associated 
tissue bank established to study the relationship between ge-
netic variation and gene expression in human tissues.19
We hypothesized that long- term childhood and adoles-
cent cancer survivors (CS) demonstrate persistent immune 
alterations of the immune cell subpopulations, resulting in 
chronic low- grade inflammation similar to changes observed 
with aging. We used the group of healthy controls as well as 
the publicly available data from the FHS and GTEx studies 
to compare selected biomarkers and lymphocyte subpopula-
tions with the results in young adult cancer survivors.
2 |  MATERIALS AND METHODS
2.1 | Subjects
We recruited consecutive, young adult childhood and ado-
lescent cancer survivors attending follow- up clinic at the 
University Hospital in Kracow, Poland. Of 72 survivors eli-
gible for participation in the study, 50 had completed evalu-
ation. Eligibility criteria included diagnosis of malignancy 
before 18 years of age; 5 or more years since completion of 
cancer treatment; and remission. Non- participants either de-
clined to participate or were not enrolled due to exclusion 
criteria. Exclusion criteria contained: time from the end of 
therapy for malignancy shorter than 5 years, relapse or sec-
ondary cancer at the time of the study or during 5 preceding 
years, acute infection, any self- reported, relevant coexisting 
diseases (e.g., chronic inflammatory diseases, hypertension, 
diabetes, chronic kidney disease), or observed significant 
abnormalities in routine blood or urine assays by discharge 
letters, and/or other available medical records. Treatment 
regimens for malignancy were based on the protocols used 
at different time periods between the years 1995 and 2009 
(Table S1). We used medical records to obtain data on de-
mographics, date of diagnosis, date of the end of therapy 
and treatment protocol. A control group of 30 age- and sex- 
matched healthy volunteers was enrolled using the same in-
clusion and exclusion criteria, except for the cancer history. 
The study was conducted in accordance with the Declaration 
of Helsinki, and the protocol was approved by the Ethics 
Committee of Jagiellonian University Medical College 
(KBET/329/B/2012). Informed consent was obtained from 
all individual participants included in the study.
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2.2 | Data from the Framingham Heart 
Study and the GTEx Project
Expression data and phenotypes were accessed from the 
Framingham Heart Study (FHS) via database of Genotypes 
and Phenotypes Project (dbGaP). Clinical characteristics 
of the FHS sample and accession numbers are presented in 
Table  S2. mRNA expression levels have been determined 
using the Affymetrix Human Exon 1.0 ST array in RNA from 
whole blood. Clinical phenotypes for the GTEx project were 
accessed via gtexportal.org. Expression levels of mRNA 
have been determined using RNA sequencing.
2.3 | Biochemical assays
Fasting blood samples were collected on the day of clinical 
evaluation. Serum levels of high- sensitivity C- reactive pro-
tein (CRP), fibrinogen, complete blood count, plasma lipid 
levels were measured within 4 hours of venipuncture (Cobas 
6000/8000 analyzer, Roche Diagnostics, Indianapolis, IN, 
USA). For extended biochemical analyses, blood samples 
were centrifuged at 2000  rpm for 10 min, and plasma was 
separated and frozen at −70ºC until assayed. Commercially 
available enzyme- linked immunosorbent assays were used 
to measure plasma levels of interleukin (IL)- 6, pentraxin- 3 
(R&D Systems, Abingdon, UK), as well as asymmetric di-
methylarginine (ADMA) and symmetric dimethylarginine 
(SDMA) (DLD Diagnostika GmbH, Hamburg, Germany).
2.4 | Flow cytometry
Blood samples for flow cytometric studies were processed 
as previously described.20,21 Additional details are provided 
in Table S3. To assess the percentage of T regulatory cells 
(Treg), CD4+CD25+FoxP3+ cells were gated from CD3+ 
T lymphocytes. B cells were gated from lymphocytes ac-
cording to CD19 expression. Then, cells were analyzed 
for IgD/CD27 expression. This separation allows to distin-
guish naïve B cells (IgD+CD27- ), memory unswitched B 
cells (IgD+CD27+), switched memory B cells and plasma 
cells (both IgD- CD27+) and double negative B cells (IgD- 
CD27- ). CD19+ B cells were also subsequently analyzed for 
differential expression of CD24/CD38 antigens.
2.5 | Statistical analysis
Data are presented as medians and interquartile range (25th 
and 75th percentiles) for continuous parameters, and numbers 
(proportions) for categorical data. Intergroup differences 
were assessed by Wilcoxon rank sum test for continuous 
variables and Fisher's exact test for proportions. To assess 
the potential relationship between age of cancer diagno-
sis and inflammatory markers, standard regression analysis 
was applied with adjustment to the participants’ gender and 
radiotherapy. Initial statistical tests were performed using 
STATISTICA, version 9.1. (StatSoft, Inc., Tulsa, Oklahoma, 
USA).
The “null” linear model of dependency between the given 
feature, and sex and age was trained on the set of controls 
and was used to obtain residuals for the given feature in both 
controls and cancer survivors. These residuals were used in 
the logistic elastic- net approach. The most robust features 
which discriminated between the two study groups were 
chosen by means of boot strapped five- fold cross- validation. 
The selected residuals were re- tested for significance using 
Wilcoxon signed- rank test. The comparison of the residu-
als for cancer survivors and controls with the individuals in 
the FHS cohort was performed by means of an analogos ap-
proach, in which we regressed out the effect of sex and age in 
the FHS cohort participants separately (using a model trained 
on the FHS cohort) and compared with the residuals obtained 
above for the in- house data. For each of the selected markers, 
the comparison was performed using the Wilcoxon signed- 
rank test. Importance index and feature importance score 
(FIS) analysis were carried out as described previously,22 
using R- package “divo” (https://CRAN.R- proje ct.org/packa 
ge=divo). A flow chart of the analysis is shown in Figure S1. 
Wilcoxon test was used to find immune marker combinations 
with positive FIS.
Deconvolution of immune cell populations using RNA 
expression was done via xCell software (https://xcell.ucsf.
edu). We tested for association between the scores for cell 
populations and age using standard linear models (with addi-
tional covariate: sex). In CS and controls we investigated the 
association between the percentage of cells and age, and time 
to end of treatment with standard Pearson product- moment 
correlation coefficient, and re- tested with Spearman rank- 
based correlation coefficient. Additionally, the associations 
between the selected biomarkers (CRP and SMDA) with cir-
culating miRNAs attributed to aging were tested. We chose 
a list of miRNAs, which were previously attributed to aging 
and inflammation.23,24 From the list of 42 miRNAs, we iden-
tified 18 that were expressed in a sufficient number of sam-
ples (below 25% of missing values). We used the elastic- net 
approach to select the strongest, and the most stable predic-
tors of the CRP and SDMA levels.
3 |  RESULTS
Survivors were studied at the median age of 22 [21– 23] 
years, 50% of the patients were females, 36% were diagnosed 
in adolescence, the mean time from the diagnosis of cancer 
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was 11 [8– 15] years. The most frequent malignancy in the 
studied group was Hodgkin lymphoma (HL)– 48%, followed 
by acute lymphoblastic leukemia (ALL)– 32%, and non- 
Hodgkin lymphoma– 12%. Solid tumors (neuroblastoma) 
accounted for less than 1% of cancers. Overall, 54% of pa-
tients underwent radiotherapy, including 5 patients with cen-
tral nervous system radiotherapy for ALL. In HL patients, 
involved field radiotherapy was used in 83% of patients. 
CRP and fibrinogen were significantly higher in survivors 
compared with healthy controls. None of the patients were 
treated with bone marrow transplantation. In regression anal-
ysis, age at diagnosis was positively associated with CRP 
(beta=0.38 ± 0.14; p = 0.008), independently of sex and ra-
diotherapy. The regression model was statistically significant 
(R2=0.21; p = 0.01). Clinical and biochemical characteristics 
of study participants are presented in Table 1.
There was a reduction in the percentage of naive T lym-
phocytes and increase in the percentage of effector memory 
T cells, and central memory T cells in survivors, compared 
with the unexposed group. The analysis of CD4+ and CD8+ 
subsets revealed that above alterations were observed partic-
ularly for CD4+ lymphocytes (Table  2, Figure  1). Among 
CD4+ T cells, the percentages of CD25+FoxP3+ (regulatory 
T cells) were comparable between the groups (7.1 [5.9– 8.0] 
vs. 7.2 [6.2– 8.3] %; p  =  0.46) in survivors and controls, 
respectively.
The percentages of lymphocytes T and subpopulations ex-
pressing activation markers were comparable except for CD38 
(34 [28.6– 42.8] % in survivors vs. 36.6 [34.3– 46.9] % in con-
trols; p = 0.044). The median surface expression of activation 
marker CD38 on T cells in CS was 1.2- fold larger compared 
with controls (707 [601– 847] vs. 579 [532– 634] (expressed as 
mean fluorescence intensity [MFI]); p < 0.001). The analysis 
of individual T cell subsets has shown that the expression of 
CD38 was increased predominantly on CD8+ lymphocytes 
(1.7- fold increase), and it remained similar in both groups 
on CD4+ lymphocytes. There was no significant differences 
between the survivors and controls in the expression of early 
activation marker CD69 on T cells. The expression of CD57 
on CD8+ lymphocytes in the studied group was lower than 
in the healthy controls (0.7- fold decrease; 24227 [16627– 
33783] vs. 33687 [24152– 41499] MFI; p < 0.01), while the 
expression of CD28 on both subsets of T cells was increased 
in comparison with the control group (1.2- fold increased ex-
pression on CD4+ lymphocytes, 1.1- fold increased expres-
sion on CD8+ lymphocytes). (Table S4, Figure S2).
T A B L E  1  Clinical characteristics of 
survivors and controls
CS (n = 50) Controls (n = 30) p- value
Age, years 22 [21– 23] 23 [22– 26] 0.032
Age at diagnosis, years 13 [8– 15] N/A N/A
Time to end of treatment, years 9.8 [7.5– 13.8] N/A N/A
Sex (female), n (%) 25 (50) 14 (46.7) 0.775
Smoking, n (%) 8 (16) 3 (10) 0.451
WHR 0.82 [0.76– 0.88] 0.79 [0.74– 0.84] 0.121
BMI, kg/m2 22.3 [20.6– 27.4] 22.3 [21.0– 23.9] 0.450
LDL, mmol/L 2.5 [2.0– 3.1] 2.0 [1.9– 2.6] 0.049
HDL, mmol/L 1.7 [1.3– 1.9] 1.6 [1.4– 1.9] 0.709
Total cholesterol, mmol/L 4.6 [4.1– 5.0] 4.2 [3.8– 4.6] 0.025
Leukocytes, 103/µl 5.47 [4.73– 6.51] 5.54 [4.71– 6.74] 0.874
Neutrophils, 103/µl 3.2 [2.6– 3.9] 2.9 [2.4– 3.7] 0.110
Lymphocytes, 103/µl 1.6 [1.4– 1.9] 1.9 [1.5– 2.3] 0.012
Monocytes, 103/µl 0.5 [0.4– 0.6] 0.6 [0.4– 0.7] 0.078
Platelets, 103/µl 217 [181– 243] 236 [199– 260] 0.065
hsCRP, mg/L 0.79 [0.33– 2.42] 0.31 [0.17– 0.57] 0.007
Fibrinogen, g/L 2.8 [2.5– 3.3] 2.2 [1.9– 2.5] <0.001
Interleukin−6, pg/ml 0.69 [0.49– 0.99] 0.71 [0.50– 0.86] 0.963
Pentraxin 3, ng/ml 1.1 [0.6– 5.9] 1.2 [0.8– 1.7] 0.745
SDMA, ng/ml 118 [99– 134] 104 [89– 118] 0.014
ADMA, µmol/L 0.36 [0.33– 0.43] 0.36 [0.33– 0.42] 0.963
Data are presented as medians [interquartile range] and percentages for categorical variables.
Abbreviations: ADMA, asymmetric dimethylarginine; BMI, body mass index; CS, cancer survivors; HDL, 
high density cholesterol; hsCRP, high sensitivity C- reactive protein; LDL, low density cholesterol; N/A, not 
applicable; SDMA, symmetric dimethylarginine; WHR, waist to hip ratio.
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There was an increase in the percentage of total CD19+ 
B lymphocytes, and naive B cells in survivors in comparison 
with controls, while the percentage of double negative B cells 
was decreased in CS when related to the control group. The 
population of CD24- CD38- B cells, both naïve and memory, 
was significantly decreased in survivors (Table 3).
To investigate the effect of sex and age on the biochemical 
parameters in the two groups, we trained a linear model on 
the control group to regress- out the effect of age and sex, 
and subsequently used this model to obtain residuals for the 
variable of interest in the CS group. Subsequently, we used 
a machine- learning approach to detect the variables which 
best discriminated between controls and CS. We applied an 
elastic- net regression model to identify parameters associ-
ated with cancer survivorship. Table 4 lists variables selected 
by elastic net regression model, and median coefficient for 
each parameter. Furthermore, using machine- learning ap-
proach based on FIS we have shown that naive and memory 
T lymphocytes, the subpopulation of naive CD4 T lympho-
cytes, CD4 cells expressing CD38, and CD19 B cells were 
strongly, positively associated with survivorship. Figure  2 
illustrates distribution and probability density of coefficients 
for selected lymphocyte subpopulations.
Analysis of associations between B cells, T cell subpop-
ulations, and age revealed different correlations among CS 
and controls. We were unable to perform the direct compari-
son between study groups at the target statistical significance 
level of 0.05 due to limited sample size. We further re- tested 
a few of these populations in the FHS and GTEx project 
cohorts, where lymphocyte subpopulations were estimated 
from mRNA expression in whole blood (Table S5). In each 
of these cases, the direction of correlation was consistent 
T A B L E  2  Comparison of T cells subsets (CD4+, CD8+) and subpopulations (naive, central memory, effector memory and TEMRA) within 
each subset in cancer survivors and controls
T cells CD4+ T cells CD8+ T cells
naive (%) CS 37.5 [29.7– 45.4] 38.3 [30.7– 49] 43.1 [29.3– 54.3]
Controls 43.6 [41.2– 48.9]b 50 [41.6– 55.5]b 47.7 [39.9– 56.7]
central memory(%) CS 19.7 [15.7– 21.7] 31.3 [24.8– 35.8] 5.0 [3.7– 6.9]
Controls 15.4 [12.7– 18.4]b 24 [21.4– 27.6]c 4.2 [3– 4.6]a 
effector memory (%) CS 29.7 [26– 37.6] 25.6 [20.8– 31.9] 38.4 [29.6– 44.1]
Controls 26.8 [22.3– 30.4]a 20.8 [17.1– 27.4] 34.8 [27.2– 38.5]
TEMRA(%) CS 9.4 [7.8– 14.4] 2.7 [2.4– 3.4] 10.6 [7– 21]
Controls 10.4 [7.6– 16] 3.4 [2.9– 4.2]b 10.9 [8.3– 18.5]
Data are presented as medians of percentages [interquartile range] of T- cell subpopulations.




F I G U R E  1  Comparison of T 
lymphocytes and T- cell subpopulations 
in cancer survivors and controls. 
Representative plots with cells obtained 
from a childhood cancer survivor patient, 
and a patient from the control group 
showing decreased percentage of naive T 
cells and increased percentages of central 
memory and effector memory T cells in 
cancer survivor (CS). (A) T lymphocytes; 
(B) CD4+ T lymphocytes; (C) CD8+ T 
lymphocytes
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with the direction of association between the current age in 
CS and the variable of interest, but not with the direction of 
correlation with age in the control group (Table 5). Time to 
end of treatment was significantly associated only with the 
percentage of B cells.
CRP was associated with two miRNAs: hsa- miR- 128- 3p 
(median coefficient: 0.019) and hsa- miR- 151a- 5p (median 
coefficient 0.1054), and SDMA was associated with hsa- 
miR- 151a- 5p (median coefficient: 0.003) in the 20- fold 
cross- validation analysis.
4 |  DISCUSSION
We report that childhood cancer survivors demonstrate a pro- 
inflammatory status characterized by increase in inflammatory 
markers: C- reactive protein and fibrinogen, as well as a shift 
toward memory and activated T lymphocytes – a decrease 
in naive T cells and an increase in memory T cells, and a 
higher expression of activation marker CD38. Furthermore, 
we demonstrate dysregulation of B cell lineage in the study 
group (Figure 3). These changes suggest a chronic immune 
activation in cancer survivors patients compared with age- 
matched individuals. Increasing age at cancer diagnosis was 
associated with higher CRP in survivors. Interleukin- 6 and 
CRP levels increase with age and are commonly used as in-
dicators of inflammation,25 and chronic low- grade inflamma-
tion in older individuals contributes to the onset of chronic 
diseases. It has been suggested that this mechanism may be 
similar, but triggered prematurely in younger childhood can-
cer survivors who were exposed to cancer treatment early in 







FHS vs. cancer 
survivors
WHR 15.557 (5.410; 58.991) N/A N/A
Neutrophils, 103/µl 0.0003 (0; 0.002) 0.564 <0.001
Lymphocytes, 103/µl −0.0002 (−0.003; 0) 0.564 <0.001
Monocytes, 103/µl −0.0001(−0.005; 0) 0.564 <0.001
Platelets, 103/µl −0.009 (−0.020; −0.0004) 0.961 0.012
MCH, pg 0.396 (0.108; 0.982) 0.964 0.004
MCHC, g/dl 0.336 (0; 0.393) 0.788 <0.001
Fibrinogen, g/L 1.617 (0.875; 8.903) N/A N/A
Interleukin−6, pg/ml −0.518 (−5.292; 0) 0.133 0.352
SDMA, ng/ml 0.017 (0.005; 0.095) 0.061 0.025
Pentraxin−3, ng/ml 0.261 (0; 1.349) N/A N/A
Higher absolute value of the coefficient reflects higher contribution to the model.
Abbreviations: FHS, Framingham Heart Study; MCH, mean corpuscular hemoglobin; MCHC, mean 
corpuscular hemoglobin concentration; N/A, not available or not applicable; SDMA, symmetric 
dimethylarginine; WHR, waist- to- hip ratio.
T A B L E  4  Parameters associated 
with cancer survivorship. Coefficients 
of parameters extracted by elastic net 
regression model, and comparison of 
selected parameters in cancer survivors and 
Controls with the FHS cohort
T A B L E  3  Distribution of B- cell subsets in cancer survivors and controls
CS Controls p- value
B cells (%) CD19 11.5 [9.3– 14.6] 6.7 [5.5– 7.5] <0.001
Naive (%) CD27- IgD+ 74.8 [62.6– 81.9] 67.8 [60.9– 75.3] 0.030
CD27- IgD+CD24- CD38- 0.8 [0.5– 1.3] 1.7 [1– 2.7] <0.001
Transitional (%) CD27- IgD- CD24+CD38+ 30.4 [21.0– 39.1] 24.6 [19.3– 28.3] 0.121
Memory unswitched (%) CD27+IgD+ 8.6 [6.3– 11.8] 10 [6.6– 13.1] 0.44
CD27+IgD+CD24- CD38- 1.3 [0.5– 2.3] 0.7 [0.3– 1.8] 0.369
Memory switched (%) CD27+IgD- 11.2 [8.8– 17.2] 14.6 [10.1– 18.9] 0.068
CD27+IgD- CD24- CD38- 4.2 [2.3– 5.4] 5.3 [4.5– 7.1] 0.003
Double negative (%) CD27- IgD- 4.1 [2.8– 5.5] 6.9 [4.2– 8.7] <0.001
Plasma cells (%) CD27+IgD- CD24- CD38+ 5.8 [3.2– 8.5] 3.9 [2.3– 5.5]] 0.087
Data are presented as medians of percentages of cell populations [interquartile range].
Abbreviation: CS, cancer survivors.
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aging, including changes in immune function.27 Long- term 
immune modulations like changes in the distribution of T cell 
subsets or in the pathways controlling T cell differentiation 
or cytokine production may persist following treatment.17 
In our study the expression of activation marker CD38 on 
CD8+ T cells was significantly higher in survivors com-
pared with controls. This increase observed in MFI reflects 
individual cell activation status but was not associated with 
increased proportion of total CD38+ cells. The main func-
tion of CD38 is the regulation of activation and proliferation 
of human T lymphocytes. A report from Bahri et al. showed 
that CD8+CD38++ T lymphocytes in humans inhibit CD4+ 
effector T cell proliferation, and may regulate immune ho-
meostasis during inflammation.28 T cells expressing high 
F I G U R E  2  Violin plot showing 
contribution of selected lymphocyte 
subpopulations discriminating cancer 
survivors from controls. Coefficients 
were obtained from the machine- learning 
approach based on FIS (see Table S2)
Correlation with age
Correlation with time to 
end of treatment
CS Controls CS
Lymphocytes 0.24; p = 0.09 0.18; p = 0.36 0.44; p = 0.23
CD3+CD45RA+ −0.14; p = 0.34 0.23; p = 0.24 −0.04; p = 0.91
CD3+CD45RA- 0.17; p = 0.23 −0.37; p = 0.05 −0.01; p = 0.97
CD3+CD45RA+CCR7+ −0.27; p = 0.06 0.12; p = 0.57 −0.18; p = 0.64
CD3+CD45RA- CCR7- 0.27; p = 0.06 −0.27; p = 0.16 0.11; p = 0.77
CD4+CD45RA+CCR7+ −0.10; p = 0.47 0.10; p = 0.61 −0.11; p = 0.77
CD3+CD38+ −0.09; p = 0.53 −0.11; p = 0.56 −0.03; p = 0.94
CD3+CD45RA+ −0.13; p = 0.37 0.28; p = 0.13 0.16, p = 0.67
CD4+CD38+ −0.15; p = 0.30 0.05; p = 0.77 0.01; p = 0.98
CD4+CD45RA+ −0.08; p = 0.58 0.27; p = 0.13 0.10; p = 0.80
CD19+ −0.09; p = 0.53 0.29; p = 0.12 −0.83; p = 0.02
Data are shown as Pearson's correlation coefficients and p- values.
Abbreviation: CS, cancer survivors.
T A B L E  5  Association between 
percentages of lymphocyte subpopulations, 
age, and time to end of treatment
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levels of CD38 have an enhanced cytokine production capa-
bility.10 A recent report by Azanan et al. was the first to draw 
attention to a similar immune phenotype in elderly subjects 
and young adult childhood leukemia survivors.29 Similar to 
this study, they reported elevated CRP and increased percent-
age of CD8+CD38+ T cells. Additionally, they observed a 
propensity to increased proportion of CD16+ monocytes. 
Therefore, these results presumably reflect chronic activa-
tion of the innate immunity in childhood leukemia survivors 
in addition to changes in the adaptive immune compartment 
which correspond to higher percentages of central memory/
effector memory T cells.
Moreover, we found that cancer survivors in our study had 
significantly higher expression of CD28 and lower expression 
of CD57 on T cells than age matched controls. CD28 is a co- 
stimulatory molecule, which has multiple functions during T- 
cell activation, proliferation, and survival.30,31 CD28 ligation 
is essential in promoting proliferation and effector function of 
conventional T cells, although it also promotes the function of 
regulatory T cells, including the production of interleukin- 10 
(Il- 10).32 It is noteworthy that Il- 10 was significantly elevated 
in young childhood ALL survivors compared with healthy 
controls.4 However, since plasma Il- 10 level was not mea-
sured in our study, and the percentages of regulatory T cells 
(CD4+CD25+FoxP3) were comparable between survivors 
and controls, the theoretical associations mentioned above 
would have to be confirmed in further studies. It could be 
hypothesized though that increased CD28 expression in CS 
might be a compensatory mechanism, as CD28 expression in 
human T cells was shown to decrease replicative senescence 
through reduced secretion of inflammatory cytokines.33
In our study, there was a significant increase in total and 
naive B lymphocytes and decrease of a B cell population de-
fined as CD27- IgD- double negative (DN) B cells in cancer 
survivors, which is inconsistent with the propensity of naive/
memory B- cell subsets observed in elderly.34,35 The reduction 
of DN B cells in cancer survivors might be a manifestation 
of dysregulation of the immune system related to cancer and/
or cancer treatment. We also found that CD38- CD24- B cells 
which are predominantly memory B lymphocytes 36 were de-
creased in cancer survivors. Our results might suggest that 
B cells may not take the key part in the generation or the 
maintenance of inflammation in cancer survivors. Although 
inflammation contributes to the development of B cells, 
the precise mechanisms of changes in B lymphocytes com-
partment associated with cancer survivorship remain to be 
elucidated. It has been suggested that chronic inflammation 
is related to development of age- related diseases.37 Cancer 
F I G U R E  3  Model of cancer- related inflammation, oxidative stress, and immunosenescence in cancer survivors. Please refer to the text for the 
detailed description. The figure was created with BioRender.com
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therapy could contribute to long- term epigenetic changes in 
immune cells, resulting in increased prevalence of inflam-
matory diseases in cancer survivors. We have previously 
reported a pro- inflammatory state among adult survivors of 
childhood ALL.38,39 An altered DNA methylation signature 
in T cells at genes involved in inflammatory processes was 
found in childhood cancer survivors over 10 years following 
treatment. Moreover, it was associated with increased fre-
quency of T cell- producing type 1 cytokines and activation 
of related signaling pathways.17
To gain further insight into molecular pathways which 
may contribute to observed results, we used publicly avail-
able data from the FHS and GTEx studies. We found that 
in FHS two miRNAs related to immunity, inflammation, 
and aging were strongly associated with levels of CRP and 
SDMA: miRNA- 128, which is linked to hematopoietic stem 
cell differentiation 40; and miRNA- 151a, which was shown to 
regulate the expression of STAT3 41 and is highly expressed 
in B- cells.42 Furthermore, the direction of correlations be-
tween the age and the selected lymphocyte subpopulations 
in FHS and GTEx cohorts corresponded to the direction of 
associations in CS, but not in the control group. This may in-
dicate that these associations may be much stronger in older 
individuals, although confounding effects due to differences 
in study design between the groups must be considered. Data 
from FHS and GTEx did not constitute a direct reference in 
our results, rather the associations between relevant clinical 
and molecular characteristics were used to elucidate the re-
sults obtained for the in- house data. Therefore these initial 
observations have yet to be confirmed in further studies.
A number of limitations of the study should be acknowl-
edged. First of all, the patients were recruited only from the 
group attending a single follow- up clinic. Additionally, pa-
tients were treated according to various protocols used be-
tween the years 1995 and 2009, and it may be debated if 
evaluation of late effects of different therapeutic approaches 
is relevant. However, the central components of chemo-
therapy treatment have not changed substantially since the 
1990  s, and therapy modifications included mainly refine-
ments of protocols using agents that have been available for 
many years.43 Another limitation is the fact that the results 
of analyses of large datasets may be affected by biological 
sources of variation such as age, sex, ethnicity, or batch 
effects. We were not able to exclude all sources of vari-
ation, we regressed out the variation due to effects of age 
and sex in the FHS cohort, although there were still some 
significant confounding effects due to differences in study 
design between the in- house group and the publicly avail-
able cohorts. The next limitation of the study is the lack of 
functional assays, which would complement the flow cyto-
metric data describing the phenotype of the immune cells and 
could provide the additional insight into the cell functional-
ity. Recently published data revealed that in cancer, T cells 
become dysfunctional due to the persistent antigen exposure. 
Dysfunctional T cells have reduced proliferative capacity, 
decreased effector function, and overexpression of multiple 
inhibitory receptors.44 As mentioned above, it cannot be ex-
cluded that chemotherapy and radiotherapy may influence 
T- cell phenotype even years after completing the therapy.45 
Low- grade inflammation and altered immune function have 
been found in survivors treated with HSCT (hematopoietic 
stem cell transplantation). These survivors in full remission 
had an altered DNA methylation signature in T cells, partic-
ularly at genes controlling oxidative stress and inflammatory 
processes. Functional assay on T cells stimulated with PMA/
ionomycin revealed Th1 phenotype and higher production of 
interferon- γ and tumor necrosis factor- α in cancer survivors 
treated with HSCT in comparison with non- irradiated sub-
jects.17 Finally, we were not able to control for all the addi-
tional factors that could affect the results. Nevertheless, in 
young survivors of a childhood- onset cancer, environmental 
exposures and lifestyle factors may have a lesser effect on the 
process of biological aging compared with adult survivors 
with chronic diseases and lifelong accumulation of various 
stressors. Lifestyle behaviors, such as smoking and alcohol 
consumption, and risk factors such as obesity were compara-
ble in survivors and controls at the time of the study, except 
for the higher total cholesterol in CS. However, we did not 
have data on physical activity, diet, exposure to chemicals, or 
various infections in the study participants.
In summary, we have shown that healthy, young child-
hood and adolescent cancer survivors are different from 
age- matched controls in terms of activation of the adaptive 
immune system and chronic, low- grade inflammation, which 
is relatively similar to aging phenotype observed in older 
population. Our findings suggest that the immunosenescent 
phenotype (i.e., decreased pool of naïve lymphocytes and 
accumulation of memory/effector cells with reduced prolif-
erative ability) in childhood cancer survivors is mainly at-
tributed to T cells, but dysregulation of B- cell lineage is also 
present. Whether those observations may apply to general 
population of pediatric cancer survivors remains to be con-
firmed in larger studies.
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